Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NECVAX-NEO1 as add-on to First-line Neoadjuvant Therapy in Triple-negative Breast Cancer
NCT06631092Phase 2Recruiting
- Sponsor
- NEC Bio B.V.
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of NECVAX-NEO1 in triple-negative breast cancer (TNBC) (2 cohorts), sponsored by NEC Bio B.V. Primary endpoints: Adverse Events, Serious Adverse Events and 2 more. Started Nov 2024; status: recruiting.
02
Drugs
NECVAX-NEO1
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06631092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06631092.